Search

Displaying results 2871 - 2880 of 8171 in total
  1. Drug

    Antithrombin Alfa

    go.drugbank.com/drugs/DB11166
    Approved

    Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations

  2. Drug

    Macimorelin

    go.drugbank.com/drugs/DB13074
    Approved

    More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. … PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.

  4. Drug

    Polaprezinc

    go.drugbank.com/drugs/DB09221
    Investigational

    Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers . It was determined that polaprezinc may be effective in p...

    International brands: Promac-D
  5. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment options for critically ill hypotensive patients who do

  6. Drug

    Benzyl alcohol

    go.drugbank.com/drugs/DB06770
    ApprovedInvestigational

    Mixtures: ZOLBENE CREMA TOPICA (CALAMINA 5% + OXIDO DE ZINC 5% + ALCOHOL BENCILICO 1%)Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  8. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombitasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly [FDA Label]. … Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

  10. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risan...